Association between Participants’ Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease

Table 2

Participants’ characteristics and PROMIS® quality of life domain scores.

PROMIS® Domains, median (IQR)	Age			Gender			Chronic Pain
	12–17 years	18-22 years	P	Male	Female	P	Yes	No	P
Fatigue	46.2 (35; 57.1)	60.7 (51; 62.6)	0.08	45.3 (39.1; 54.1)	57.1 (48.8; 62)	0.11	61.5 (60.9; 62)	49 (39.9; 60)	0.17
Pain	49.2 (32.2; 59)	54.3 (51; 60.4)	0.34	50.1 (42; 59)	52.2 (32.2; 57.5)	0.5	67.5 (65.5; 69.5)	49.9 (39.1; 57.7)	0.04
PF - UE	50.2 (45.3; 57.2)	56.4 (44.2; 56.4)	0.89	50.7 (49.1; 57.2)	46.5 (44.3; 56.4)	0.15	33.3 (25.8; 40.8)	50.7 (46.4; 56.4)	0.05
PF - mobility	46.2 (41.3; 53.1)	44.1 (41.8; 54.1)	0.96	47.6 (43.8; 55.8)	43.5 (36.4; 47.3)	0.03	35.45 (27.6; 43.3)	46.2 (42.9; 53.1)	0.09
Anxiety	41.5 (32.4; 50.2)	57.3 (46.9; 61)	0.06	47.2 (36.9; 55.4)	41 (36.9; 59.7)	0.97	62.1 (60.9; 63.3)	42.3 (36.9; 55.4)	0.05
Depression	37.5 (31.9; 47.9)	62.1 (34.6; 63.1)	0.14	40.9 (34.6; 47.9)	42.3 (31.9; 62.2)	0.81	64.35 (62.2; 66.5)	37.5 (34.2; 52.1)	0.05

P-value < 0.05 was statistically significant and p-value of 0.05 was borderline significant (highlighted in bold).
All PROMIS® data were reported as T-scores.
IQR: interquartile range; PF: physical function; PROMIS: patient reported outcomes measurement information system; UE: upper extremities.
Chronic pain defined as daily pain for a minimum of 3 months and/or using long-acting narcotics (Morphine Sulphate Controlled Release or MS Contin) 2-3 times daily for a minimum of 3 months.
Higher PROMIS® scores indicated more severe or worse fatigue, pain interference, depression, or anxiety, while lower PROMIS® scores indicated more limited, impaired, or worse upper extremity physical function or mobility physical function.
We evaluated each PROMIS domain across patient groups separately with no adjustment for multiple testing.